You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma
|
|---|---|
| Published in |
BMC Cancer, October 2016
|
| DOI | 10.1186/s12885-016-2800-5 |
| Pubmed ID | |
| Authors |
Yiyu Lu, Weiguang Gu, Jin Deng, Hua Yang, Wen Yang |
| Abstract |
Concurrent chemotherapy and radiation is the standard treatment for unresectable stage III Lung adenocarcinoma. However, no optimal concurrent chemotherapeutic regimen has been described. This study aimed to assess concurrent pemetrexed, nedaplatin and thoracic intensity-modulated radiotherapy followed by consolidation pemetrexed/nedaplatin for unresectable Stage IIIA/B lung adenocarcinoma. Patients with unresectable stage III lung adenocarcinoma received thoracic intensity-modulated radiotherapy at 60-64 Gy in 30-32 fractions, concurrently with two cycles of 500 mg/m(2) pemetrexed, with nedaplatin doses escalating from 60 mg/m(2) (level 1) to 70 mg/m(2) (level 2) and 80 mg/m(2) (level 3). Consolidation consisted of three pemetrexed/nedaplatin (500 mg/m(2), 60 mg/m(2)) cycles every 3 weeks after concurrent therapy. The primary objective of the safety was to determine the maximum-tolerated dose (MTD). The secondary endpoints included response rate, PFS and OS. Fifteen patients were enrolled, including 3, 6 and 6 individuals in the first, second, and third dose levels, respectively. Three cases of dose-limiting toxicities (grade 3 hepatitis, pneumonitis, and grade 4 thrombocytopenia), including one and two patients at levels 2 and 3, respectively, were observed and resulted in discontinued/delayed treatment. Response rates were 86.7 % (95 % confidence interval [CI], 64.2-97.8 %) and 64.3 % (95 % CI, 38.3-85.4 %) at chemoradiation and treatment completions, respectively. Median OS was 30.0 months (95 % CI, 16.4-43.6 months); 2-year OS was 44.0 % (95 % CI, 18.7-69.2 %). Median PFS was 12.0 months (95 % CI, 6.9-17.0 months), and the 2-year PFS 27.0 % (95 % CI, 4.7-49.3 %). Full dose 500 mg/m(2) of pemetrexed and nedaplatin 70 mg/m(2) could be used safely with thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma. Further evaluation of stage III lung adenocarcinoma management is warranted. This study was retrospectively registered at Chinese Clinical Trial Registry ( ChiCTR-OPN-16008316 , April 2016). |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 16 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 3 | 19% |
| Student > Master | 2 | 13% |
| Lecturer | 2 | 13% |
| Student > Postgraduate | 2 | 13% |
| Researcher | 2 | 13% |
| Other | 1 | 6% |
| Unknown | 4 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Nursing and Health Professions | 4 | 25% |
| Medicine and Dentistry | 4 | 25% |
| Computer Science | 1 | 6% |
| Agricultural and Biological Sciences | 1 | 6% |
| Social Sciences | 1 | 6% |
| Other | 1 | 6% |
| Unknown | 4 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 October 2016.
All research outputs
#20,344,065
of 22,890,496 outputs
Outputs from BMC Cancer
#6,510
of 8,328 outputs
Outputs of similar age
#277,267
of 320,333 outputs
Outputs of similar age from BMC Cancer
#103
of 151 outputs
Altmetric has tracked 22,890,496 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,328 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,333 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 151 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.